NEW YORK (GenomeWeb) – Empire Genomics said today it has tapped Quadpharma to manufacture analyte-specific reagents using current good manufacturing principles for its clients in the research, clinical, and pharmaceutical industries.
Empire, located in Buffalo, NY, said it partnered with the Clarence, NY-based contract manufacturer to meet a growing demand for GMP-manufactured ASRs, and noted that the companies have completed their first batch of products. The company said its clients are increasingly requesting that more stringent quality controls be applied in early phases of their research and development and clinical services to meet requirements for test performance.
"This relationship is critical in continuing to ensure that we meet the needs of our customers from research through clinical trials and ultimately the launching of companion diagnostic tests," Empire Genomics President and CEO Anthony Johnson said in a statement .
He added that the partnership is currently in its first phase and that Empire will work with Quadpharma to manufacture in vitro diagnostic products in the future.
Financial terms of the agreement were not disclosed.